Summary
In many cell systems, resistance to cytotoxic drugs is acquired by the amplification and/or overexpression of the multidrug resistance (mdr) gene, which codes for the glycoprotein, p170 (P-glycoprotein). Moreover, in a variety of malignant tumours there is increasing evidence of the relationship between the DNA ploidy pattern of patients and their prognosis. In this study we aimed to evaluate these two potential indicators of constitutive drug resistance in human colorectal tumours. We employed a method to quantify simultaneously, on a per cell basis,mdr gene expression (using the C219 monoclonal antibody for P-glycoprotein) and nuclear DNA content with high-resolution bivariate flow cytometry. The study was performed on a human coloncarcinoma-derived cell line (LoVo) and its doxorubicinresistant variant (LoVo/Dx) and on tumour samples and adjacent normal mucosa from 35 untreated patients with colon cancer. The P-glycoprotein was found in both LoVo and LoVo/Dx cells with levels slightly lower in the parental than in the resistant subline (P, NS). A multidrug-resistant specific probe for mRNA expression and Western blot assay confirmed the specificity of p170 expression. All of the colon cancer with unimodal diploid DNA distribution and all the normal colonic mucosa samples showed P-glycoprotein expression, without a statistically significant difference in median values between tumours and normal samples. Tumours with bimodal DNA distribution showed median values of P-glycoprotein expression of their hyperdiploid cell clones significantly higher than those of their diploid clones and of the tumours with unimodal DNA distribution (P<0.005). Our results show the feasibility of bivariate flow-cytometric analysis of P-glycoprotein expression and DNA content on clinical material and support the hypothesis that the MDR phenotype and DNA ploidy together may influence the biological behaviour of colon cancer in vivo.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- MDR:
-
multidrug resistance phenotype
- mdr :
-
multidrug resistance gene
- FITC:
-
fluorescein isothiocyanate
- PBS:
-
phosphate-buffered saline
References
Astler VB, Coller FA (1954) The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 139:846–851
Beck WT (1990) Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II and other factors. Cancer Treat Rev 17:11–20
Chabner B (1987) The oncologic end game. J Clin Oncol 4:626–638
Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277–1287
Curt GA, Clendinin N, Chabner BA (1984) Drug resistance in cancer. Cancer Treat Rep 68:87–99
Danova M, Giaretti W, Merlo F, Mazzini G, Gaetani P, Geido E, Gentile S, Butti G, DiVinci A, Riccardi A (1991) Prognostic significance of nuclear DNA content in human neuroepithelial tumors. Int J Cancer 48:663–667
Danova M, Giordano M, Mazzini G, Riccardi A (1990) Expression of p53 protein during the cell cycle measured by flow cytometry in human leukemia. Leukemia Res 14:417–422
Epstein J, Xiao H, Oba BK (1989) P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood 74:913–917
Fojo AT, Ueda K, Slamon D, Poplak DJ, Gottesman MM, Pastan I (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265–271
Giaretti W, Santi L (1990) Tumor progression by DNA flow cytometry in human colorectal cancer. Int J Cancer 45:597–603
Giaretti W, Danova M, Geido, Mazzini G, Sciallero S, Aste H, Scivetti P, Riccardi A, Marsano B, Merlo F, D'Amore ESG (1991) Flow cytometric DNA index in the prognosis of colorectal cancer. Cancer 77:1921–1927
Grandi M, Geroni C, Giuliani FC (1986) Isolation and characterization of a human colon adenocarcinoma cell line resistant to doxorubicin. Br J Cancer 54:515–518
Grogan T, Dalton W, Rybsky J, Spier C, Meltzer P, Richter L, Gleason M, Pindur J, Cline A, Scheper R, Tsuruo T, Salmon S (1990) Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies. Lab Invest 63:815–824
Kartner N, Riordan J, Ling V (1983) Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221:1285–1287
Kartner N, Evernden-Porelle D, Bradley G, Ling V (1985) Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316:820–823
Kaye S (1988) The multidrug resistance phenotype. Br J Cancer 58, 691–696
Look AT, Hayes FA, Nitsche R, McWilliams NB, Green A (1984) Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 311:231–235
Merkel DE, Dressler LG, McGuire WL (1987) Flow cytometry, cellular DNA content and prognosis in human malignancy. J Clin Oncol 5:1690–1703
Nooter K, Herweijer H (1991) Multidrug resistance (mdr) genes in human cancer. Br J Cancer 63:663–669
Pastan I, Gottesman M (1987) Multiple-drug resistance in human cancer. N Engl J Med 316:1388–1393
Redmond SMS, Joncourt F, Buser, K, Ziemiecki M, Altermatt H, Fey M, Margison G, Cerny T (1991) Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res 51:2092–2097
Rew DA, Wilson GD, Taylor I, Weaver PC (1991) Proliferation characteristics of human coclorectal carcinomas measured in vivo. Br J Surg 78:60–66
Rothenberg M, Ling V (1989) Multidrug resistance: molecular biology and clinical relevance. J Natl Cancer Inst 81:907–910
Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, N.Y.
Scagliotti GV, Michelotto F, Kalikatzaros G, Leonardo E, Cappia S, Gubetta L, Borasio, Pozzi E (1991) Detection of multidrug resistance associated p-170 glycoprotein in previously untreated non small cell lung cancer. Anticancer Res 11:2207–2210
Scala S, Pacelli R, Iaffaioli RV, Normanno N, Pepe S, Frasci G, Genua G, Tsuruo T, Tagliaferri P, Bianco AR (1991) Reversal of Adriamycin resistance by recombinant alpha-interferon in multidrug resistant human colon carcinoma LoVo-doxorubicin cells. Cancer Res 51:4898–4902
Toffoli G, Viel A, Tumiotto L, Bisontin G, Rossi C, Boiocchi M (1991) Pleiotropic-resistant phenotype is a multifactorial phenomenon in human colon carcinoma cell lines. Br J Cancer 63: 51–56
Vollrath V, Chianale J, Gonzalez S, Duarte I, Andrade L, Ibanez L (1991) Multidrug resistance gene and P-glycoprotein expression in gastric adenocarcinoma and precursors lesions. Virchows Arch [B] 60:133–138
Volm M, Effert T (1990) Relationship of DNA ploidy to chemoresistance of tumors as measured by in vitro tests. Cytometry 11:406–410
Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Kouskoulis GK, Kuszak JR, Klusen LF, Grogan TM, Saclarides TJ, Roninson IB (1991) Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51:2720–2726
Author information
Authors and Affiliations
Additional information
Research supported in part by C.N.R. target projects “Oncology” and “Biotechnology and Bioinstrumentation”, by A.I.R.C. and by I.R.C.C.S. San Matteo
Rights and permissions
About this article
Cite this article
Danova, M., Giordano, M., Erba, E. et al. Flowcytometric analysis of multidrug-resistance-associated antigen (P-Glycoprotein) and DNA ploidy in human colon cancer. J Cancer Res Clin Oncol 118, 575–580 (1992). https://doi.org/10.1007/BF01211799
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01211799